Molecular recognition at adenine nucleotide (P2) receptors in platelets

Seminars in Thrombosis and Hemostasis

Volumn 31, Issue 2, 2005, Pages 205-216

  Jacobson, Kenneth A ^a   Mamedova, Liaman ^a   Joshi, Bhalchandra V ^a   Besada, Pedro ^a   Costanzi, Stefano ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Agonist; Antagonist; G protein coupled receptors; Mutant; P2Y receptors

Indexed keywords

2' DEOXY 6 N METHYLADENOSINE 3',5' BISPHOSPHATE; 3 [7 [2 (3,4 DIFLUOROPHENYL)CYCLOPROPYLAMINO] 5 PROPYLTHIO 1,2,3 TRIAZOLO[4,5 D]PYRIMIDIN 3 YL] 5 HYDROXYMETHOXY 1,2 CYCLOPENTANEDIOL; 6 N (2 METHYLTHIOETHYL) 2 (3,3,3 TRIFLUOROPROPYLTHIO)ADENOSINE PHOSPHATE; ADENINE NUCLEOTIDE; ALPHA,BETA METHYLENEADENOSINE TRIPHOSPHATE; AR C67085MX; AROMATIC COMPOUND; CARBOCYCLIC NUCLEOSIDE; CLOPIDOGREL; CT 50547; G PROTEIN COUPLED RECEPTOR; INS 49266; LIGAND; MRS 2216; MRS 2279; MRS 2298; MRS 2395; MRS 2496; MRS 2500; MRS 2576; MRS 2596; NF 279; NF 449; PRASUGREL; PURINE P2 RECEPTOR; PURINE P2X1 RECEPTOR; PURINE P2Y1 RECEPTOR; PURINE P2Y12 RECEPTOR; PURINERGIC RECEPTOR AFFECTING AGENT; PURINERGIC RECEPTOR BLOCKING AGENT; RHODOPSIN; TICLOPIDINE; UNCLASSIFIED DRUG; YM 254890;

ANIMAL CELL; BINDING AFFINITY; CLINICAL TRIAL; DRUG BINDING SITE; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HUMAN; HUMAN CELL; MOLECULAR MODEL; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVIEW; SHEAR STRESS; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOSIS;

ADENOSINE DIPHOSPHATE; BLOOD PLATELETS; DRUG DESIGN; FIBRINOLYTIC AGENTS; HUMANS; LIGANDS; MEMBRANE PROTEINS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 18044392545     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-869526     Document Type: Review

References (70)

1. Kunapuli SP, Ding Z, Dorsam RT, et al. ADP receptors-targets for developing antithrombotic agents. Curr Pharm Des 2003;9:2303-2316
2. Jacobson KA, Jarvis MF, Williams M. Perspective: purine and pyrimidine (P2) receptors as drug targets. J Med Chem 2002;45:4057-4093
3. 12 receptors in platelet procoagulant activity. Arterioscler Thromb Vasc Biol 2003;23:1941-1947
4. 12, play a role in controlling shape change in human platelets. Platelets 2003;14:15-20
5. 1 cation channel in thrombosis of small arteries in vivo. J Exp Med 2003;198:661-667
6. Costanzi S, Mamedova L, Gao ZG, Jacobson KA. Architecture of P2Y nucleotide receptors: structural comparison based on sequence analysis, mutagenesis, and homology modeling. J Med Chem 2004;47:5393-5404
7. 1 receptor in surface expression and activation processes. J Biol Chem 1999;274:14639-14647
8. 1 receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites. J Med Chem 1998;41:1456-1466
9. 1 receptor. Mol Pharmacol 1997;52:499-507
10. 1 receptor. Mol Pharmacol 1998;54:1118-1123
11. Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001;409:202-207
12. Foster CJ, Prosser DM, Agans JM, et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001;107:1591-1598
13. 1 receptor: structure activity relationships and receptor docking. J Med Chem 2001;44:3092-3108
14. Palczewski K, Kumasaka T, Hori T, et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000;289: 739-745
15. 1 receptor. Drug Dev Res 2002;57:173-181
16. Nicke A, Baumert HG, Rettinger J, et al. P2X1 and P2X3 receptors form stable trimers: a novel structural motif of ligand-gated ion channels. EMBO J 1998;17:3016-3028
17. 1/2 receptors show a novel sensitivity to extracellular pH. J Pharmacol Exp Ther 2002; 300:673-680
18. 1 receptors. Biochem Biophys Res Commun 2001;289:700-704
19. 2 receptor. Br J Pharmacol 2003;138:131-136
20. Egan TM, Cox JA, Voigt MM. Molecular structure of P2X receptors. Curr Top Med Chem 2004;4:821-829
21. Cusack NJ, Hourani SMO. Adenosine, adenine nucleotides, and platelet function. In: Phillis JW, ed. Adenosine and Adenine Nucleotides as Regulators of Cellular Function. Boca Raton, FL: CRC Press; 1991:121-131
22. 13 receptor. Mol Pharmacol 2003;64:104-112
23. Fischer B, Boyer JL, Hoyle CHV, et al. Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5′-triphosphate. J Med Chem 1993;36:3937-3946
24. Bodor ET, Waldo GL, Hooks SB, et al. Purification and functional reconstitution of the human P2Y12 receptor. Mol Pharmacol 2003;64:1210-1216
25. Boyer JL, Siddiqi S, Fischer B, et al. Identification of potent P2Y-purinoceptor agonists that are derivatives of adenosine 5′- monophosphate. Br J Pharmacol 1996;118: 1959-1964
26. Fischer B, Chulkin A, Boyer JL, et al. 2-thioether 5′-O-(1- thiotriphosphate) adenosine derivatives as new insulin secretagogues acting through P2Y-receptors. J Med Chem 1999;42:3636-3646
27. 1 receptor agonists. J Med Chem 2002;45:5384-5396
28. 1 receptor ligands. J Med Chem 2000;43:829-842
29. 6 receptors. J Med Chem 2002;45:208-218
30. 1 receptor agonists. J Med Chem 2002;45:2090-2100
31. 13 receptors by conformational constraint of an ADP analogue. J Pharmacol Exp Therap 2004;311:1038-1043
32. 1-receptor. Mol Pharmacol 1996;50:1323-1329
33. Brown SG, King BF, Kim YC, Burnstock G, Jacobson KA. Activity of novel adenine nucleotide derivatives as agonists and antagonists at recombinant rat P2X receptors. Drug Dev Res 2000;49:253-259
34. 1 receptor antagonists. Bioorg Med Chem 2004;12:1769-1779
35. 1 receptor antagonist. Br J Pharmacol 2002;135:2004-2010
36. 1 receptor with a high affinity radiolabeled antagonist. Mol Pharmacol 2002;62:1249-1257
37. 1 receptor antagonist. Eur J Pharmacol 2001;412:213-221
38. 1 receptor antagonists. J Med Chem 2003;46:4974-4987
39. 1 receptor. Biochem Pharmacol 2004;68:1995-2002
40. 1-receptor antagonists. J Org Chem 2002;67:8063-8071
41. 1 receptor: structure activity relationships and receptor docking. J Med Chem 2001;44:3092-3108
42. Xu B, Stephens A, Kirschenheuter G, et al. Acyclic analogues of adenosine bisphosphates as P2Y receptor antagonists: phosphate substitution leads to multiple pathways of inhibition of platelet aggregation. J Med Chem 2002;45:5694-5709
43. Charlton SJ, Brown CA, Weisman GA, et al. PPADS and suramin as antagonists at cloned P2Y- and P2U-purinoceptors. Br J Pharmacol 1996;118:704-710
44. 1 receptor-mediated responses. J Auton Nerv Syst 2000;81: 171-177
45. Taniguchi M, Nagai K, Arao N, et al. YM-254890, a novel platelet aggregation inhibitor produced by Chromobacterium sp. QS3666. J Antibiot 2003;56:358-363
46. Glänzel M, Bültmann R, Starke K, Frahm AW. Members of the acid blue 129 family as potent and selective P2Y-rcceptor antagonists. Drug Dev Res 2003;59:64-71
47. Brown J, Brown CA. Evaluation of reactive blue 2 derivatives as selective antagonists for P2Y receptors. Vascul Pharmacol 2002;39:309-315
48. 1 purinoceptor. Br J Pharmacol 1996;117:1111-1118
49. 1 receptor signaling without affecting nucleotide binding. Biochem Pharmacol 2004;68:231-237
50. 6 nucleotide receptors. Biochem Pharmacol 2004;67:1763-1770
51. 2T receptor: a novel approach to antithrombotic therapy. J Med Chem 1999;42:213-220
52. 11 receptor. Br J Pharmacol 1999;128:1199-1206
53. th ACS National Meeting, Division of Medicinal Chemistry, March 23-27, 2003; New Orleans, LA
54. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000;84:891-896
55. i-linked P2T antagonist, CS-747. Br J Pharmacol 2001;132: 47-54
56. 12). Bioorg Med Chem Lett 2001;11:1805-1808
57. Fretz H, Houille O, Hilpert K, Peter O, Breu V, et al. Novel pyrazolidine-3,5-dione derivatives are P2Y12 receptor antagonists and inhibit ADP-triggered blood platelet aggregation Paper presented at: American Chemical Society 229th National Meeting, March 13, 2005; SanDiego, CA
58. 12 platelet receptor. Haematologica 2002; 87(suppl 1):22 (abst)
59. Cusack NJ, Hourani SMO. Structure activity relationships for adenine nucleotide receptors on mast cells, human platelets, and smooth muscle. In: Jacobson KA, Daly JW, Manganiello V eds. Purines in Cellular Signalling: Targets for New Drugs. New York: Springer; 1990:254-259
60. 4A) as potential anti-platelet-aggregation agents. Proc Natl Acad Sci U S A 1992;89:2370-2373
61. King BF. Molecular biology of P2X purinoreceptors. In: Burnstock G, Dobson JG Jr, Liang BT, Linden J, eds. Cardiovascular Biology of Purines. Boston: Kluwer Academic Publishers; 1998:159-186
62. Bianchi BR, Lynch KJ, Tourna E, et al. Pharmacological characterization of recombinant human and rat P2X receptor subtypes. Eur J Pharmacol 1999;376:127-138
63. Cinkilic O, King BF, van der Giet M, et al. Selective agonism of group I P2X receptors by dinucleotides dependent on a single adenine moiety. J Pharmacol Exp Ther 2001;299:131-136
64. Lambrecht G, Braun K, Damer M, et al. Structure-activity relationships of suramin and pyridoxal-5′-phosphate derivatives as P2 receptor antagonists. Curr Pharm Des 2002;8: 2371-2399
65. 1 receptors. Naunyn Schmiedebergs Arch Pharmacol 2001;364: 285-290
66. 1 receptor antagonist. Eur J Med Chem 2004;39:345-357
67. 1 receptors. J Med Chem 2001;44: 340-349
68. 3 receptors. Drug Dev Res 2001;53:281-291
69. Surprenant A, Schneider DA, Wilson HL, Galligan JJ, North RA. Functional properties of heteromeric P2X(1/5) receptors expressed in HEK cells and excitatory junction potentials in guinea-pig submucosal arterioles. J Auton Nerv Syst 2000;81: 249-263
70. 1 receptors. Br J Pharmacol 1999;128:981-988